These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 29791065

  • 1. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X, Li X, Zhang T, Zhao L.
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
    [Abstract] [Full Text] [Related]

  • 2. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
    Zhao M, Zhang T, Li G, Qiu F, Sun Y, Zhao L.
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
    [Abstract] [Full Text] [Related]

  • 3. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
    Wang C, Wang P, Yang LP, Pan J, Yang X, Ma HY.
    Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
    [Abstract] [Full Text] [Related]

  • 4. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
    Inoue K, Suzuki E, Takahashi T, Yamamoto Y, Yazawa R, Takahashi Y, Imai K, Miyakawa K, Inoue Y, Tsuji D, Hayashi H, Itoh K.
    Epilepsy Res; 2014 Aug; 108(6):1046-51. PubMed ID: 24888247
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.
    Yagi M, Nakamura T, Okizuka Y, Oyazato Y, Kawasaki Y, Tsuneishi S, Sakaeda T, Matsuo M, Okumura K, Okamura N.
    Pediatr Int; 2010 Oct; 52(5):744-8. PubMed ID: 20456087
    [Abstract] [Full Text] [Related]

  • 7. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K, Takahashi T, Yamamoto Y, Suzuki E, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K.
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [Abstract] [Full Text] [Related]

  • 8. Risk factors for hyperammonemia in pediatric patients with epilepsy.
    Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, Inoue K, Itoh K, Kagawa Y, Inoue Y.
    Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
    [Abstract] [Full Text] [Related]

  • 9. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
    Goto S, Seo T, Hagiwara T, Ueda K, Yamauchi T, Nagata S, Ando Y, Ishitsu T, Nakagawa K.
    J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
    Chen ZJ, Wang XD, Wang HS, Chen SD, Zhou LM, Li JL, Shu WY, Zhou JQ, Fang ZY, Zhang Y, Huang M.
    Seizure; 2012 Mar; 21(2):110-7. PubMed ID: 22055352
    [Abstract] [Full Text] [Related]

  • 12. CPS1 T1405N polymorphism, HDL cholesterol, homocysteine and renal function are risk factors of VPA induced hyperammonemia among epilepsy patients.
    Chen L, Tian Q, Zhang M, Chen D, Gao X, Yang H, Li H, Li C, Wen J, Li Y, Tian X, Chen P.
    Epilepsy Res; 2019 Aug; 154():139-143. PubMed ID: 31151073
    [Abstract] [Full Text] [Related]

  • 13. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
    Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y.
    Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Association of valproic acid and 2-propyl-4-pentenoic acid concentrations with adverse reaction in 254 Chinese patients with epilepsy.
    Ma H, Zhu W, Wang C, Pan J, Yang X, Luo J, Wang P.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Jul 28; 44(7):775-783. PubMed ID: 31413215
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical significance of CYP2C9-status guided valproic acid therapy in children.
    Bűdi T, Tóth K, Nagy A, Szever Z, Kiss Á, Temesvári M, Háfra E, Garami M, Tapodi A, Monostory K.
    Epilepsia; 2015 Jun 28; 56(6):849-55. PubMed ID: 25967074
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.